Warren Ladiges

EBioMedicine · 2018

⊕ Open access · OA

Fisetin is a senotherapeutic that extends health and lifespan

▲ 997

Nature · 2021

⊕ Preprint · OA

An aged immune system drives senescence and ageing of solid organs

▲ 938

JCI Insight · 2020

⊕ Open access · CC-BY

Canagliflozin extends life span in genetically heterogeneous male but not female mice

▲ 125

Aging Cell · 2017

⊕ Open access · CC-BY

Circulating levels of monocyte chemoattractant protein‐1 as a potential measure of biological age in mice and frailty in humans

▲ 117

Aging · 2020

⊕ Preprint · CC-BY

ATM is a key driver of NF-κB-dependent DNA-damage-induced senescence, stem cell dysfunction and aging

▲ 114

Aging Cell · 2009

⊕ Open access · OA

Lifespan extension in genetically modified mice

▲ 102

Aging Cell · 2019

⊕ Open access · CC-BY

Glycine supplementation extends lifespan of male and female mice

▲ 96

GeroScience · 2020

⊕ Open access · OA

Heterochronic parabiosis regulates the extent of cellular senescence in multiple tissues

▲ 69

Ageing Research Reviews · 2016

◌ Citation only

Molecular pathology endpoints useful for aging studies

▲ 59

GeroScience · 2019

⊕ Open access · OA

Validation of a geropathology grading system for aging mouse studies

▲ 41

GeroScience · 2022

⊕ Open access · OA

Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice

▲ 32

Scientific Reports · 2022

⊕ Open access · CC-BY

Reduced expression of mitochondrial complex I subunit Ndufs2 does not impact healthspan in mice

▲ 31

Cell Cycle · 2013

⊕ Open access · OA

Chronic rapamycin treatment or lack of<i>S6K1</i>does not reduce ribosome activity in vivo

▲ 30

Scientific Reports · 2022

⊕ Open access · CC-BY

Short term treatment with a cocktail of rapamycin, acarbose and phenylbutyrate delays aging phenotypes in mice

▲ 23

bioRxiv (Cold Spring Harbor Laboratory) · 2020

⊕ Preprint · OA

Canagliflozin Extends Lifespan in Genetically Heterogeneous Male But Not Female Mice

▲ 12

GeroScience · 2024

⊕ Open access · CC-BY

A cocktail of rapamycin, acarbose, and phenylbutyrate prevents age-related cognitive decline in mice by targeting multiple aging pathways

▲ 11

Aging Pathobiology and Therapeutics · 2019

⊕ Open access · CC-BY

The rationale for testing drug combinations in aging intervention studies

▲ 4

bioRxiv (Cold Spring Harbor Laboratory) · 2024

⊕ Preprint · CC-BY

A drug cocktail of rapamycin, acarbose, and phenylbutyrate enhances resilience to features of early-stage Alzheimer’s disease in aging mice

▲ 3

Aging Pathobiology and Therapeutics · 2021

⊕ Open access · CC-BY

Physical performance is enhanced in old mice fed a short term diet medicated with rapamycin, acarbose, and phenylbutyrate

▲ 2

Aging Pathobiology and Therapeutics · 2022

⊕ Open access · CC-BY

Pharmaceutical interventions to slow human aging. Are we ready for cocktails?

▲ 2

Aging Pathobiology and Therapeutics · 2021

⊕ Open access · CC-BY

The antidiabetic drug acarbose suppresses age-related lesions in C57BL/6 mice in an organ dependent manner

▲ 2

bioRxiv (Cold Spring Harbor Laboratory) · 2025

⊕ Preprint · CC-BY

The gerotherapeutic drugs rapamycin, acarbose, and phenylbutyrate extend lifespan and enhance healthy aging in house crickets

▲ 1

bioRxiv (Cold Spring Harbor Laboratory) · 2022

⊕ Preprint · CC-BY

A cocktail of rapamycin, acarbose and phenylbutyrate prevents age-related cognitive decline in mice by altering aging pathways

▲ 1

Research Square · 2026

⊕ Preprint · CC-BY

The gerotherapeutic drugs rapamycin, acarbose, and phenylbutyrate extend lifespan and enhance healthy aging in house crickets

▲ 0

bioRxiv (Cold Spring Harbor Laboratory) · 2021

⊕ Preprint · CC-BY

Short term treatment with a cocktail of rapamycin, acarbose and phenylbutyrate slows aging in mice

▲ 0